Related Experiment Video
Updated: Jul 11, 2025

Phage-mediated Delivery of Targeted sRNA Constructs to Knock Down Gene Expression in E. coli
Published on: March 20, 2016
Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications
Mohadeseh Hassannia1, Mahin Naderifar2, Shakiba Salamy3
1Department of Genetic, Faculty of Science, Islamic Azad University, Tehran, Iran.
Abstract:
In recent decades, the expansion of multi and extensively drug-resistant (MDR and XDR) bacteria has reached an alarming rate, causing serious health concerns. Infections caused by drug-resistant bacteria have been associated with morbidity and mortality, making tackling bacterial resistance an urgent and unmet challenge that needs to be addressed properly. Endolysins are phage-encoded enzymes that can specifically degrade the bacterial cell wall and lead to bacterial death. There is remarkable evidence that corroborates the unique ability of endolysins to rapidly digest the peptidoglycan particular bonds externally without the assistance of phage. Thus, their modulation in therapeutic approaches has opened new options for therapeutic applications in the fight against bacterial infections in the human and veterinary sectors, as well as within the agricultural and biotechnology areas. The use of genetically engineered phage enzymes (EPE) promises to generate endolysin variants with unique properties for prophylactic and therapeutic applications. These approaches have gained momentum to accelerate basic as well as translational phage research and the potential development of therapeutics in the near future. This review will focus on the novel knowledge into EPE and demonstrate that EPE has far better performance than natural endolysins and phages in dealing with antibiotic-resistant infections. Therefore, it provides essential information for clinical trials involving EPE.
Insights
Genetically engineered phage enzymes (EPE) offer a promising solution to combat multi and extensively drug-resistant bacteria. These novel enzymes show superior performance over natural endolysins and phages in treating resistant infections.
Area of Science:
- Microbiology
- Biotechnology
Background:
- Rising rates of multi and extensively drug-resistant (MDR and XDR) bacteria pose significant global health threats.
- Bacterial infections linked to drug resistance contribute to increased morbidity and mortality.
- Endolysins, phage-encoded enzymes, degrade bacterial cell walls, offering a potential antimicrobial strategy.
Purpose of the Study:
- To review novel knowledge on genetically engineered phage enzymes (EPE) as a therapeutic strategy.
- To highlight the enhanced performance of EPE compared to natural endolysins and phages.
- To provide information relevant for clinical trials involving EPE.
Main Methods:
- Review of existing literature on endolysins and genetically engineered phage enzymes.
- Analysis of studies demonstrating the efficacy of EPE against antibiotic-resistant bacteria.
- Focus on the potential of EPE in therapeutic and prophylactic applications.
Main Results:
- Genetically engineered phage enzymes (EPE) exhibit superior performance in combating antibiotic-resistant infections.
- EPE demonstrate unique properties for therapeutic and prophylactic applications.
- These engineered enzymes accelerate phage research and therapeutic development.
Conclusions:
- EPE represent a significant advancement in the fight against drug-resistant bacterial infections.
- The unique properties of EPE offer new therapeutic options across human, veterinary, agricultural, and biotechnological sectors.
- Further research and clinical trials involving EPE are warranted to fully realize their potential.
Related Concept Videos
Lytic Cycle of Bacteriophages
Biological Methods for Microbial Control
Gene Regulation in Microbial Communities: Quorum Sensing
Microorganisms in Medicine and Therapeutics
DNA Bacteriophages
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

